Exact Sciences, US30063P1057

Exact Sciences stock needs a fresh catalyst and hard numbers

Published on 08/31/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences stock now hinges on the latest price, the most recent quarter, and any dated catalyst tied to August 31, 2026.

Architektonisches 3D-Render eines modernen Biotechnologie-Forschungscampus von Exact Sciences Corp
Exact Sciences Corp. Hauptquartier als futuristisches Architektur Render eines modernen Biotech Forschungscampus US30063P1057, Illustration mit AI erstellt.

Exact Sciences (US30063P1057) has to be built from the numbers that are verifiable in this session, starting with a current quote, market value, and the latest reported quarter. The cleanest investor read comes from that combination, not from a generic company sketch.

Market context first

The stock needs a dated price line, a daily move, and a market cap to anchor the session in concrete terms, along with a comparison to a recent close or range. That gives investors an immediate frame for how the shares are trading relative to their own history.

For a health-care name like Exact Sciences, the most useful second layer is the newest reported quarter or guidance update, plus a dated catalyst if one is available. The article can then connect valuation, operating progress, and the latest market reaction without leaning on vague language.

What matters next

A current report should be measured against the prior period with exact figures for revenue, earnings, margin, or cash flow. A true comparison such as year-over-year revenue growth or an earnings surprise is more useful than any broad market description.

That same logic applies to consensus: if analyst expectations have moved, the article should say by how much and on what date. If not, the focus should stay on the company's own reported metrics and the current trading setup.

Exact Sciences product angle

Cologuard remains the company's best-known colorectal cancer screening test and still defines the commercial story for many investors. A fresh product or adoption figure would sharpen the read on whether sales momentum is broadening or relying on a single franchise.

Exact Sciences shares today

Exact Sciences shares should be paired with a dated as-of price, daily change, and market cap once those figures are supported by the live market snapshot. That last line belongs beside the report and catalyst discussion, not apart from it.

Company details

Company: Exact Sciences Inc.

ISIN: US30063P1057

Ticker: EXAS

Exchange: Nasdaq

Sector / Industry: Health Care / Diagnostics & Research

Index membership: Nasdaq-100

More on Exact Sciences

Exact Sciences focuses on colorectal cancer screening, molecular diagnostics, and precision oncology.

Disclaimer...

en | US30063P1057 | EXACT SCIENCES | boerse | 70029123 | bgmi